Ceralasertib, also known as AZD6738, showed synergistic activity in combination with olaparib in ATM-deficient cancer cells, and was found to be tolerable and effective for prolonging progression-free survival of patients with platinum-sensitive relapsed epithelial ovarian cancer.491 VX-803 and BAY1895344 are also selective ATR inhibitors currently in phase I trials.492 Although numerous studies have indicated that inhibition of DNA-PKcs is deleterious to cancer cells, with very promising results, further pre-clinical and clinical trials should be conducted to obtain more substantial data. Here, PRKDC is linked to cancer.